This test used to identify distant or local metastasis from prostatic carcinoma. Among 60 to 75% of patients with bone metastasis are found to have it in increased numbers, among 20 percent of patients with extensions into periprostatic soft tissue without bone involvement and 5 percent of patients having carcinoma are confined to the gland.
